Characteristics of patients with metastatic malignant melanoma in Colombia: Results of the Epidemiologic Registry of Malignant Melanoma REMMEC ACHO.

Aylen Vanessa Ospina Serrano ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Bogotá, Colombia info_outline Aylen Vanessa Ospina Serrano, Juan David Ortiz Diaz, Fernando Contreras, Isabel Munevar, Paola Jimenez, William Armando Mantilla, Henry Idrobo, Pedro Ramos, Ray Manneh Kopp, Natalia Arango Acevedo, Daniel Andres Santa, Giovanna Patricia Rivas Tafurt, Alicia Quiroga, Claudia Vargas, Andres Yepes, Carmen Marcela Alcala Castro, Mauricio Lema, Isabel Chinchia, July Andrea Russi Noguera, Ivan Camilo Triana

Authors Aylen Vanessa Ospina Serrano ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Bogotá, Colombia info_outline Aylen Vanessa Ospina Serrano, Juan David Ortiz Diaz, Fernando Contreras, Isabel Munevar, Paola Jimenez, William Armando Mantilla, Henry Idrobo, Pedro Ramos, Ray Manneh Kopp, Natalia Arango Acevedo, Daniel Andres Santa, Giovanna Patricia Rivas Tafurt, Alicia Quiroga, Claudia Vargas, Andres Yepes, Carmen Marcela Alcala Castro, Mauricio Lema, Isabel Chinchia, July Andrea Russi Noguera, Ivan Camilo Triana Organizations ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Bogotá, Colombia, Fundación valle del Lili, Cali, Colombia, Instituto Nacional de Cancerologia, Universidad El Bosque, Bogota, Colombia, Hospital Militar Central, Fundación Cardioinfantil, Hemato Oncólogos Asociados., Bogota, Colombia, Hemato Oncólogos Asociados, Clínica Los Cobos MC, Bogota, Colombia, Hematoncólogos, Fundacion CardioInfantil, Bogota, Colombia, Centro Médico Julián Coronel, Universidad del Valle, Cali, Colombia, Clínica Universitaria Colombia, Sanitas, Oncocare, Bogota, Colombia, Sociedad de Oncología y Hematología del Cesar (SOHEC), Valledupar, Colombia, Clinica Medellin - Centro Oncologico de Antioquia, Medellín, Colombia, Clínica Medellín, Medellin, Colombia, Clínica de Occidente, Cali, Colombia, Hospital Pablo Tobon Uribe, Medellin, Colombia, Centro Oncologico de Antioquia, Medellín, Colombia, Hospital Universitario San Vicente Fundación, Medellin, Colombia, Clinica La Costa, Barranquilla, Colombia, Clinica Astorga, Medellín, Colombia, Cosmitet, Bogota, Colombia, Hospital Universitario San Ignacio- Centro Javeriano de Oncologia, Bogota, Colombia, Hospital Universitario Fundación Santa Fe de Bogota, Bogotá, Colombia Abstract Disclosures Research Funding No funding sources reported Background: The features and prognostic factors of patients with metastatic malignant melanoma are not well established in our country. Our objective is to collect and analyze the characteristics of a cohort of Colombian patients. Methods: Analytical cohort study based on the Epidemiologic Registry of Malignant Melanoma in Colombia (REMMEC). Data were collected between January 2011 and December 2023. Patients older than 18 years with a confirmed diagnosis of advanced melanoma were included. Descriptive analysis of demographic and clinical characteristics and survival analysis using Cox regression and Kaplan-Meier models were performed. Results: 322 patients were included. Median age was 66.5 years (range 55-76), 56% (180) of patients were men, 87% (280) had advanced disease at diagnosis, most (82%) with non-brain metastases and 51% (164) with multiple organ involvement. Table 1. For first-line treatment, patients received single-agent immunotherapy (37.26%), doublet immunotherapy (10.25%), targeted therapy (9%), and chemotherapy (7.14%), while 29% received best supportive care BSC. In the second line, single agent immunotherapy 9.32%, targeted therapy (4.34%), doublet immunotherapy 3.42%, chemotherapy (5%) and 77% received BSC. In the third line, only 9% (29) of patients were able to receive any therapy. Median follow-up was 16 months (IQR 7-32), median progression-free survival (PFS) was 8 months (IQR 4-35) and median overall survival (OS) was 23 months (IQR 9-66). OS in the first-line setting with immunotherapy as monotherapy was 23 months (IQR 12-40) HR 0.40 P 0.035 and with doublet immunotherapy 16 months (IQR 8-28) HR 0.16 P 0.005 Clinical characteristics associated with lower median OS were brain metastasis (HR 1,95 P 0.001), ECOG 3-4 (HR 5,49 P 0.001) and multiple metastatic disease (HR 2,15 P 0.001). According to acral vs. non-acral histologic type, the median OS was 26 vs. 44 months, respectively (HR 1.30 P 0.26). Conclusions: In our cohort of patients with metastatic melanoma, we found clinical outcomes similar to those reported in the worldwide literature. It is necessary to continue the registry and follow-up of patients to identify specific prognostic factors. Characteristics of the population (N 322). ECOG 0 37% 120) 1-2. 54% (175) 3-4 8% (27) Phototype I-II 22% (70) III-IV 28% (90) Primary site Cutaneous Melanoma 69% (221) Mucosal Melanoma 15% (49) Uveal 2.8% (9) Unknown 50% (162) Histologic type Acral lentiginous 41% (71) Nodular 26%(46) Superficial Spreading 15% (27) History of sun exposure Unknown 55% (176) Chronic 24% (78) Intermittent 14% (46) Socio-economic level Low 31% (100) BRAF mutation Unknown 48%(155) Positive 50%( 200)